ARCT — Arcturus Therapeutics Holdings Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeSmall CapMomentum Trap
- $415.94m
- $238.00m
- $12.36m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.86 | ||
| Price to Tang. Book | 2.86 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.08 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -67.46% | ||
| Return on Equity | -72.46% | ||
| Operating Margin | -285.28% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 13 | 15.75 | 20.79 | 9.54 | 12.36 | 126.42 | 107.3 | -9.52% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Arcturus Therapeutics Holdings Inc. is a late-stage global clinical messenger ribonucleic acid (mRNA) medicines company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its mRNA platform, the Company's lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose levels. The Company's products under developmental stage using STARR technology are ARCT-021, ARCT-154 and ARCT-165. Its COVID-19 vaccine candidate, ARCT-021, which is based on its STARR technology platform is through Phase II clinical trials. Its LUNAR-FLU Vaccine consists of Liver Franchise ARCT-810 (LUNAR-OTC) and Lung Franchise ARCT-032 (LUNAR-CF).
Directors
- Peter Farrell NEC (79)
- Joseph Payne PRE (49)
- Andrew Sassine CFO (56)
- Padmanabh Chivukula COO (41)
- Steven Hughes OTH (54)
- Lance Kurata OTH (51)
- James Barlow IND (62)
- Edward Holmes IND (80)
- Jing Marantz IND (57)
- Magda Marquet IND (62)
- Last Annual
- December 31st, 2021
- Last Interim
- September 30th, 2022
- Incorporated
- January 28th, 2019
- Public Since
- August 6th, 2014
- No. of Shareholders
- 14
- No. of Employees
- 177
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 26,492,869
- Address
- 10628 Science Center Dr Ste 250, SAN DIEGO, 92121-1132
- Web
- https://arcturusrx.com/
- Phone
- +1 8589002660
- Auditors
- Ernst & Young LLP
Upcoming Events for ARCT
Q4 2022 Arcturus Therapeutics Holdings Inc Earnings Call
Arcturus Therapeutics Holdings Inc To Present At Guggenheim Healthcare Talks: Genomic Medicines & Rare Disease Day
Q1 2023 Arcturus Therapeutics Holdings Inc Earnings Release
Arcturus Therapeutics Holdings Inc Annual Shareholders Meeting
Q2 2023 Arcturus Therapeutics Holdings Inc Earnings Release
Similar to ARCT
89bio
NASDAQ Global Market
AcelRx Pharmaceuticals
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Arcturus Therapeutics Holdings share price?
As of Today at 18:26 UTC, shares in Arcturus Therapeutics Holdings are trading at $15.70. This share price information is delayed by 15 minutes.
How has the Arcturus Therapeutics Holdings share price performed this year?
Shares in Arcturus Therapeutics Holdings last closed at $15.70 and the price had moved by -44.09% over the past 365 days. In terms of relative price strength the Arcturus Therapeutics Holdings share price has underperformed the S&P500 Index by -36.03% over the past year.
What are the analyst and broker recommendations for Arcturus Therapeutics Holdings?
The overall consensus recommendation for Arcturus Therapeutics Holdings is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Arcturus Therapeutics Holdings dividend yield?
Arcturus Therapeutics Holdings does not currently pay a dividend.
Does Arcturus Therapeutics Holdings pay a dividend?
Arcturus Therapeutics Holdings does not currently pay a dividend.
When does Arcturus Therapeutics Holdings next pay dividends?
Arcturus Therapeutics Holdings does not currently pay a dividend.
How do I buy Arcturus Therapeutics Holdings shares?
To buy shares in Arcturus Therapeutics Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Arcturus Therapeutics Holdings?
As of the previous close price of $15.70, shares in Arcturus Therapeutics Holdings had a market capitalisation of $415.94m.
Where are Arcturus Therapeutics Holdings shares listed?
Here are the trading details for Arcturus Therapeutics Holdings:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ARCT
What kind of share is Arcturus Therapeutics Holdings?
Based on an overall assessment of its quality, value and momentum Arcturus Therapeutics Holdings is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Arcturus Therapeutics Holdings share price forecast for 2023?
The analyst consensus target price for shares in Arcturus Therapeutics Holdings is $39.83. That is 153.69% above the last closing price of $15.70.
Analysts covering Arcturus Therapeutics Holdings currently have a consensus Earnings Per Share (EPS) forecast of -$3.13 for the next financial year.
What is the trend in the Arcturus Therapeutics Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arcturus Therapeutics Holdings. Over the past six months, its share price has outperformed the S&P500 Index by +6.1%.
As of the last closing price of $15.70, shares in Arcturus Therapeutics Holdings were trading -8.45% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Arcturus Therapeutics Holdings PE Ratio?
The Arcturus Therapeutics Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $15.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings' management team is headed by:
- Peter Farrell - NEC
- Joseph Payne - PRE
- Andrew Sassine - CFO
- Padmanabh Chivukula - COO
- Steven Hughes - OTH
- Lance Kurata - OTH
- James Barlow - IND
- Edward Holmes - IND
- Jing Marantz - IND
- Magda Marquet - IND